Spinraza denials in California external review
In the California DMHC record, independent physician reviewers decided 14 published external-review cases involving Spinrazaand overturned the plan’s denial in 100%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Spinraza denials
| Category | Decisions | Overturned |
|---|---|---|
| Spinal Muscular Atrophy | 10 | 100% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 7 | 100% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 7 | 100% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The parent of the patient has requested authorization and coverage for Spinraza (nusinersen). The current medical literature and guidelines support treatment for all symptomatic patients with spinal muscular atrophy (SMA) above two years of age with either Spinraza or Evrysdi. However, there is a lack of clinical trials showing the superiority of either Spinraza or Evrysdi. Thus, the choice of medication involves specific patient characteristics and preferences. The U.S. Food and Drug Administration (FDA) initially approved Spinraza based on data from a randomized placebo-controlled study of symptomatic infants with SMA. Longer-term follow-up studies have also reported on the long-term efficacy of Spinraza in patients with early onset SMA, with patients showing superior motor outcomes when started on therapy before two years of age.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Spinraza dosing schedule of first dose on day 1, second dose on day 15, third dose on day 30, fourth dose on day 60, and then maintenance doses every four (4) months. Findings: The physician reviewer found that the medical literature, Hoy noted that SMA is an autosomal recessive neuromuscular disorder characterized by degeneration of spinal motor neurons and poses significant adverse outcome in affected population. The author reports that SMA is “most commonly caused by insufficient levels of survival motor neuron (SMN) protein (which is critical for motor neuron maintenance) secondary to deletions or mutations in the SMN1 gene.” Spinraza is a U.S. Food and Drug Administration (FDA) approved medication for the treatment of SMA.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Spinraza, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY